Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [
Bone metastases
Diffusion-weighted MRI
Positron emission tomography/computed tomography
Whole-body MRI
[18F]-fluorodeoxyglucose
[18F]-sodium fluoride
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
10
08
2018
accepted:
19
11
2018
pubmed:
7
12
2018
medline:
19
5
2020
entrez:
4
12
2018
Statut:
ppublish
Résumé
To compare [ Thirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUV Twenty-two patients (median age, 58.6 years, range, 40-79 years) completing baseline and 8-week imaging were included in the final analysis. Per-patient % change in NaF SUV FDG PET/CT and WB-MRI best predicted clinical non-PD and both FDG and NaF PET/CT predicted PFS < 24 weeks. Lesional response heterogeneity occurs with all modalities and flare is common with NaF PET/CT.
Identifiants
pubmed: 30506455
doi: 10.1007/s00259-018-4223-9
pii: 10.1007/s00259-018-4223-9
pmc: PMC6450846
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Fluorides
Q80VPU408O
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
821-830Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK (GB)
ID : C1519/A16463
Organisme : Breast Cancer Now
ID : 2012NovPR013
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT203148/Z/16/Z
Pays : United Kingdom
Références
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Eur J Cancer. 2000 Mar;36(4):476-82
pubmed: 10717523
Semin Nucl Med. 2001 Jan;31(1):28-49
pubmed: 11200203
Acad Radiol. 2002 Aug;9(8):913-21
pubmed: 12186440
J Clin Oncol. 2003 Jun 1;21(11):2101-9
pubmed: 12775735
J Bone Miner Res. 2003 Dec;18(12):2215-22
pubmed: 14672357
AJR Am J Roentgenol. 2006 Jun;186(6):1783-6
pubmed: 16714674
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6236s-6242s
pubmed: 17062707
Breast Cancer Res Treat. 2007 Sep;105(1):87-94
pubmed: 17268819
Radiology. 2008 Apr;247(1):189-96
pubmed: 18372468
Eur J Radiol. 2010 Feb;73(2):280-7
pubmed: 19070445
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Nucl Med. 2010 Apr;51(4):521-7
pubmed: 20237040
Radiology. 2010 Nov;257(2):523-31
pubmed: 20829534
Eur Radiol. 2011 Aug;21(8):1713-8
pubmed: 21472473
Eur Radiol. 2011 Oct;21(10):2169-77
pubmed: 21710270
Cancer Causes Control. 2012 Jan;23(1):103-12
pubmed: 22037907
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):450-60
pubmed: 22183107
EJNMMI Res. 2011 Jun 07;1(1):4
pubmed: 22214491
Ann Nucl Med. 2012 Jun;26(5):426-35
pubmed: 22477261
Eur Radiol. 2014 Mar;24(3):610-8
pubmed: 24097303
J Magn Reson Imaging. 2014 May;39(5):1049-78
pubmed: 24510426
Eur J Cancer. 2014 Oct;50(15):2519-31
pubmed: 25139492
J Nucl Med. 2015 Feb;56(2):222-8
pubmed: 25593113
J Nucl Med. 2015 Mar;56(3):354-60
pubmed: 25635138
Eur J Radiol. 2015 Apr;84(4):623-30
pubmed: 25641009
J Bone Oncol. 2014 May 09;3(2):40-8
pubmed: 26909296
PLoS One. 2016 Apr 28;11(4):e0153840
pubmed: 27123931
J Clin Oncol. 2016 Sep 1;34(25):3069-103
pubmed: 27217461
J Nucl Med. 2016 Dec;57(12):1872-1879
pubmed: 27445292
Radiology. 2017 Apr;283(1):168-177
pubmed: 27875103
J Nucl Med. 2017 Apr;58(4):523-532
pubmed: 28232605
J Clin Oncol. 2017 Aug 20;35(24):2829-2837
pubmed: 28654366
Cancer. 1983 Aug 15;52(4):610-4
pubmed: 6861098